

Factsheet | The Biosimilar Medicines Group



About the Biosimilar Medicines Group


The **Biosimilar Medicines Group**, a sector group of **Medicines for Europe**, represents the leading companies in the biosimilar medicines space. The Biosimilar Medicines Group members bring competition to the biologicals market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

Medicines for Europe represents the European generic, biosimilar and value added medicines industries, which provide high-quality cost-competitive medicines to millions of Europeans. The vision of **Medicines for Europe** is to provide sustainable access to high quality medicines for all European patients, based on 5 important pillars: **patients, quality, value, sustainability** and **partnership**.

The Biosimilar Medicines Group is open to **Medicines for Europe** and non-**Medicines for Europe** members.

For more information please follow us at www.medicinesforeurope.com and on Twitter [@biosimilarsEU](https://twitter.com/biosimilarsEU)

Biosimilar Medicines: Key Facts



Biosimilar Medicines Group Membership

COMPANIES

Accord Healthcare
Apobiologix
Cinfa Biotech
CinnaGen
Egis
Formycon
Fresenius Kabi
Gedeon Richter

Mylan
Polpharma
Samsung Bioepis
Sandoz
Stada
Teva

NATIONAL ASSOCIATIONS

APOGEN (Portugal)
BOGIN (Netherlands)
British Biosimilars Association (a group of BGMA) (UK)
CAFF (Czech Republic)
FGA (Finland)
FGL (Sweden)
GEMME (France)
GENAS (Slovakia)
IEIS (Turkey)
IGL (Denmark)

Italian Biosimilars Group (a group of Assogenerici) (Italy)
Intergenerika (Switzerland)
MAGYOSZ (HU)
Medaxes (BE)
Medicines for Ireland
Probiosimilars (a group of ProGenerika) (Germany)
VGA (LT)

